In a podcast interview with Bio2040, CEO Owen Roberts discusses M4K Pharma’s business model and why open science and sharing can be the path to finding medicines for rare diseases like DIPG.
Bio2040 interviews M4K Pharma’s Owen Roberts [Podcast]
Previous
Previous
M4K’s Lemon Face Challenge for DIPG
Next
Next